Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) — The “RNA Therapy Market – Global Forecast 2026-2032” has been added to ResearchAndMarkets.com’s offering.
The RNA therapy market is expected to grow from USD 18.77 billion in 2025 to USD 19.70 billion in 2026, progressing at a CAGR of 6.40% to reach USD 28.99 billion by 2032. This growth is propelled by steady clinical proof, revamped supply chain methods, and increased regional investments. Industry leaders are enhancing strategic positions through next-generation RNA modalities, offering adaptable product portfolios and commercialization strategies. The rise in demand for personalized medicine is driving innovation, necessitating a robust infrastructure for scalability and accessibility, underscoring the need for strategic clarity as RNA therapy integrates with the broader biopharmaceutical sector.
Scope & Segmentation of the RNA Therapy Market
- Therapeutic Areas: Applications include cardiovascular illnesses, genetic disorders, infectious diseases (bacterial and viral), metabolic and neurological diseases, oncology targets like hematological cancers, and solid tumors, as well as rare conditions such as Gaucher disease, neuromuscular disorders, and sickle cell disease. These broaden the scope of RNA-based therapeutics.
- Delivery Platforms: Comprising exosomes, lipid nanoparticles, polymer carriers, and viral vectors, which impact targeting ability, immune profile, production scale, and clinical trial timing. These platforms enable developers to tailor delivery methods to specific objectives.
- End-User Groups: Biotechnology companies, pharmaceutical manufacturers, hospitals, clinics, and research institutes. Their needs shape commercialization strategies, facility investments, and market entry timings, creating a diverse and dynamic ecosystem.
- Geographic Regions: Covers the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting unique regulatory challenges, adoption rates, and infrastructure capabilities. Global teams must navigate regional nuances in technology uptake, trial conduction, and market penetration.
Key Takeaways: Strategic Considerations in RNA Therapeutics
- RNA platforms have transitioned from research concepts to validated therapies, driven by molecular engineering innovations and production advancements.
- Scientific innovation, delivery platform selection, supply chain resilience, and partnerships with healthcare institutions equally impact success.
- Strategic distinction relies on synchronizing delivery technologies and pipeline priorities to align with dynamic program needs and competitive pressures.
- Collaborative efforts between biotech firms and established pharmaceutical companies accelerate clinical adoption and ease operational and regulatory integration.
- Heightened end-user demands, such as quick production cycles for infectious diseases and targeted rare condition therapies, are reshaping commercialization strategies and capital resource allocation.
- Regional factors such as evolving policies in Asia-Pacific and payer complexities in Europe, the Middle East & Africa directly affect commercialization, reimbursement, and access planning.
Why This Report Matters for Decision-Makers
- Offers prioritized insights on RNA therapy pipelines and delivery technologies, clarifying platform impact and therapeutic focus.
- Helps adapt regulatory and supply chain strategies to shifting policies, supporting global operational flexibility.
- Guides planning for commercial partnerships, manufacturing growth, and payer engagement, aligning with strategic and patient access goals.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 184 |
| Forecast Period | 2026 – 2032 |
| Estimated Market Value (USD) in 2026 | $19.7 Billion |
| Forecasted Market Value (USD) by 2032 | $28.99 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
Companies Featured
The key companies profiled in this RNA Therapy market report include:
- Alnylam Pharmaceuticals, Inc.
- Arcturus Therapeutics Holdings, Inc.
- Arrowhead Pharmaceuticals, Inc.
- BioNTech SE
- CureVac N.V.
- Eli Lilly and Company
- Ionis Pharmaceuticals, Inc.
- Moderna, Inc.
- Sarepta Therapeutics, Inc.
- Silence Therapeutics plc
- Stoke Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/ax5c18
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
